ADVANTAGES

In the coming 10 years I hope we will have effective methods for early diagnosis. Right now, researchers have developed a new test that is able to detect abnormal alpha-synuclein in the spinal fluid of people with Parkinson’s with remarkable specificity and sensitivity, at an early stage of the disease. It is early days, but the test is promising. There is also a new neuro-protective strategy where LRRK2 kinase inhibitors are being trialled as therapies for Parkinson’s disease. Researchers have discovered an interaction in neurons that contributes to Parkinson’s disease, and they have shown that drugs currently in development may block the process. The hope is that these will bring major improvements in the quality of life for people with Parkinson’s – life expectancy will improve and the progression of the condition may be slowed or even stopped.

Testimonials

Satisfied customers are saying